Public Relations Global Network

Public Relations Global Network company information, Employees & Contact Information

More than 1,000 clients across six continents depend on the combined resources of the Public Relations Global Network (PRGN) to deliver targeted public relations campaigns in more than 80 markets around the world. With revenues of more than $100 million (U.S.), PRGN is among the world’s top five public relations networks. PRGN harnesses the resources of 40 independent public relations firms, 50 offices and more than 800 communications professionals to connect international companies and organizations with individual and culturally diverse markets globally. Visit PRGN online at: www.prgn.com.
Looking for a particular Public Relations Global Network employee's phone or email?

Public Relations Global Network Questions

News

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review - CGTLive®

FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review CGTLive®

FDA Accepts BLA for PRGN-2012 for Recurrent Respiratory Papillomatosis - HCPLive

FDA Accepts BLA for PRGN-2012 for Recurrent Respiratory Papillomatosis HCPLive

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial - The Lancet

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial The Lancet

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 PR Newswire

78% Business Leaders Attribute Brand Influence to Digital Presence | PRGN, The Newmark Group at World PR Day - Techeconomy

78% Business Leaders Attribute Brand Influence to Digital Presence | PRGN, The Newmark Group at World PR Day Techeconomy

After 27 years Precigen gets an approval | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

After 27 years Precigen gets an approval | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Promising treatment for recurrent respiratory papillomatosis - National Cancer Institute (.gov)

Promising treatment for recurrent respiratory papillomatosis National Cancer Institute (.gov)

Newmark, PRGN Celebrate 2025 World PR Day, Release Industry Report - THISDAYLIVE

Newmark, PRGN Celebrate 2025 World PR Day, Release Industry Report THISDAYLIVE

Precigen cuts workforce by 20% to focus on gene therapy for benign tumours - Pharmaceutical Technology

Precigen cuts workforce by 20% to focus on gene therapy for benign tumours Pharmaceutical Technology

ASCO24 Updates: Dr. Scott Norberg on Breakthrough HPV Vaccine for RRP | PRGN-2012 Clinical Trial - Oncodaily

ASCO24 Updates: Dr. Scott Norberg on Breakthrough HPV Vaccine for RRP | PRGN-2012 Clinical Trial Oncodaily

Gene Therapy Shows Promise for Recurrent Respiratory Papillomatosis - European Medical Journal

Gene Therapy Shows Promise for Recurrent Respiratory Papillomatosis European Medical Journal

Five Advanced Therapeutics to Watch in 2H 2025 - CGTLive®

Five Advanced Therapeutics to Watch in 2H 2025 CGTLive®

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis PR Newswire

Precigen Reports Full Year 2024 Financial Results and Business Updates - PR Newswire

Precigen Reports Full Year 2024 Financial Results and Business Updates PR Newswire

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response - PR Newswire

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire

Fearey Strengthens Leadership as It Evolves into a Fully Integrated Communications Agency - PR Newswire

Fearey Strengthens Leadership as It Evolves into a Fully Integrated Communications Agency PR Newswire

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients - PR Newswire

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients PR Newswire

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers - PR Newswire

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers PR Newswire

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting - PR Newswire

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting PR Newswire

JMP maintains Precigen stock $6 target on PRGN-2012 optimism - Investing.com

JMP maintains Precigen stock $6 target on PRGN-2012 optimism Investing.com

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients - PR Newswire

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients PR Newswire

FDA Accepts for Review Precigen RRP Gene Therapy Candidate - Genetic Engineering and Biotechnology News

FDA Accepts for Review Precigen RRP Gene Therapy Candidate Genetic Engineering and Biotechnology News

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis - PR Newswire

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis PR Newswire

Precigen Bets On Gene Therapies After First FDA Approval - Finimize

Precigen Bets On Gene Therapies After First FDA Approval Finimize

Precigen’s Promising Phase 2 Study: PRGN-2009 and Pembrolizumab for Cervical Cancer - TipRanks

Precigen’s Promising Phase 2 Study: PRGN-2009 and Pembrolizumab for Cervical Cancer TipRanks

Precigen laying off 20% of staff, pausing programs to eke out cash for approval filing - Fierce Biotech

Precigen laying off 20% of staff, pausing programs to eke out cash for approval filing Fierce Biotech

Precigen: RRP Targeting With AdenoVerse Technology Platform - Seeking Alpha

Precigen: RRP Targeting With AdenoVerse Technology Platform Seeking Alpha

Public Relations Global Network (PRGN) Hits 50-Member Mark - GlobeNewswire

Public Relations Global Network (PRGN) Hits 50-Member Mark GlobeNewswire

At ESGCT, Precigen Data Supports Its Lead Candidate as RRP Treatment - Genetic Engineering and Biotechnology News

At ESGCT, Precigen Data Supports Its Lead Candidate as RRP Treatment Genetic Engineering and Biotechnology News

Analysts Are Bullish on Precigen Stock (PGEN) Amid Positive Pipeline Developments - The Globe and Mail

Analysts Are Bullish on Precigen Stock (PGEN) Amid Positive Pipeline Developments The Globe and Mail

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis - Stock Titan

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis Stock Titan

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis - Nature

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis Nature

Newmark Group Officially Inducted Into Public Relations Global Network (PRGN) | Tech | Business | Economy - Techeconomy

Newmark Group Officially Inducted Into Public Relations Global Network (PRGN) | Tech | Business | Economy Techeconomy

Stakeholders call for strategic communication, ethics to build public trust - The Guardian Nigeria News

Stakeholders call for strategic communication, ethics to build public trust The Guardian Nigeria News

PRGN and Newmark Group Launch Global Expert Panel to Accelerate Growth in Africa’s Tourism and Travel Sectors - Capitalfm.co.ke

PRGN and Newmark Group Launch Global Expert Panel to Accelerate Growth in Africa’s Tourism and Travel Sectors Capitalfm.co.ke

The Newmark Group becomes the latest member of PRGN - CitiNewsroom.com

The Newmark Group becomes the latest member of PRGN CitiNewsroom.com

World PR Day: Newmark, PRGN Move To Tackle Polarisation, Misinformation - Leadership Newspapers

World PR Day: Newmark, PRGN Move To Tackle Polarisation, Misinformation Leadership Newspapers

Top Public Relations Global Network Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant